Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01888744

Acronym

Avanti

Enrollment

120

Registered

2013-06-28

Start date

2010-09-30

Completion date

2013-06-30

Last updated

2013-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reproductive Endocrinology, Fertility, Optimal Stimulation Protocol

Keywords

Intracytoplasmic sperm injection (ICSI), PGD, GnrH agonist, GnRH antagonist

Brief summary

The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).

Detailed description

Patients will be randomized at the outpatient clinic in two groups.

Interventions

DRUGGnRH agonist

DRUGGnRH antagonist

DRUGhP-hMG

DRUGHuman chorionic gonadotropin

induction of final oocyte maturation

DRUGProgesterone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Inclusion criteria

* ≤ 39 years the day of oocyte retrieval * BMI ≤ 29 * cycle rank 1 * menstrual cycle 25-36 days * PGD or preimplantation genetic screening (PGS) requested * ICSI * Single embryo transfer (SET) on day 5

Exclusion criteria

* Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria) * Hormonal disturbances * Endometriosis grade III and IV

Design outcomes

Primary

Measure	Time frame
Number of day 3 embryos for biopsy available	up to 6 weeks

Secondary

Measure	Time frame
Number of mature cumulus-oocyte complexes	up to 6 weeks
clinical pregnancy rate	up to 9 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026